Parameter | Placebo | Glycopyrrolate | Aclidinium | Total | |||||
---|---|---|---|---|---|---|---|---|---|
(n = 149) | 3 μg BID (n = 91) | 6.25 μg BID (n = 92) | 12.5 μg BID (n = 145) | 25 μg BID (n = 54) | 50 μg BID (n = 149) | 100 μg BID (n = 59) | 400 μg BID (n = 94) | (N = 378) | |
Mean (SD) age, years | 57.7 (7.65) | 54.5 (5.90) | 54.4 (5.90) | 56.9 (7.37) | 59.6 (8.98) | 56.4 (7.49) | 59.4 (7.65) | 54.6 (5.92) | 59.0 (8.05) |
Age <65 years, n (%) | 120 (80.5) | 89 (97.8) | 90 (97.8) | 124 (85.5) | 40 (74.1) | 126 (84.6) | 42 (71.2) | 92 (97.9) | 278 (73.5) |
Gender, n (%) | |||||||||
Female | 80 (53.7) | 49 (53.8) | 49 (53.3) | 76 (52.4) | 30 (55.6) | 73 (49.0) | 34 (57.6) | 50 (53.2) | 197 (52.1) |
Male | 69 (46.3) | 42 (46.2) | 43 (46.7) | 69 (47.6) | 24 (44.4) | 76 (51.0) | 25 (42.4) | 44 (46.8) | 181 (47.9) |
Race, n (%) | |||||||||
White | 131 (87.9) | 81 (89.0) | 83 (90.2) | 132 (91.0) | 51 (94.4) | 135 (90.6) | 49 (83.1) | 84 (89.4) | 339 (89.7) |
Black/African American | 17 (11.4) | 10 (11.0) | 9 (9.8) | 13 (9.0) | 3 (5.6) | 13 (8.7) | 10 (16.9) | 10 (10.6) | 37 (9.8) |
American Indian/Alaskan Native | 1 (0.7) | 0 | 0 | 0 | 0 | 1 (0.7) | 0 | 0 | 2 (0.5) |
Post-bronchodilator FEV1, n (%) | |||||||||
<50% predicted | 60 (40.3) | 34 (37.4) | 34 (37.0) | 59 (40.7) | 28 (51.9) | 62 (41.6) | 25 (42.4) | 35 (37.2) | NA |
≥50% predicted | 89 (59.7) | 57 (62.6) | 58 (63.0) | 86 (59.3) | 26 (48.1) | 87 (58.4) | 34 (57.6) | 59 (62.8) | NA |